Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting


You May Also Like

TESARO Announces Data Presentations at the 2018 American Association for Cancer Research Annual Meeting

WALTHAM, Mass., March 14, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical ...

Incysus to Present at BioCentury Future Leaders Conference

NEW YORK, March 21, 2018 (GLOBE NEWSWIRE) -- Incysus, Ltd., a biopharmaceutical company focused ...